Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.45 | 0.73 | -0.36 | 2.90 |
| FCF Yield | -1.04% | -1.65% | -2.45% | -1.53% |
| EV / EBITDA | -58.24 | -32.50 | -27.95 | -37.20 |
| Quality | ||||
| ROIC | -5.27% | -5.84% | -10.97% | -8.68% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.67 | 0.85 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.78% | 28.79% | -40.37% | -40.84% |
| Safety | ||||
| Net Debt / EBITDA | 5.05 | 4.17 | 3.21 | 4.63 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |